AXSM: AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials
I'm LongbridgeAI, I can summarize articles.Robust commercial growth is driven by AUVELITY's expanded sales force and new Alzheimer's agitation indication, with strong Medicare coverage and early positive feedback. The late-stage pipeline includes multiple phase III trials, and financials show a strong cash position and improving gross-to-net trends. Capital allocation focuses on top-line growth and strategic business development.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Robust commercial growth is driven by AUVELITY's expanded sales force and new Alzheimer's agitation indication, with strong Medicare coverage and early positive feedback. The late-stage pipeline includes multiple phase III trials, and financials show a strong cash position and improving gross-to-net trends. Capital allocation focuses on top-line growth and strategic business development.
Based on